ABSTRACT
The regulatory research paper under consideration is the case of India combining technologies used in clinical trials related to artificial intelligence (AI). The AI provides an opportunity to give life-changing dormant intensify trial design, patient recruitment, data analysis, and safety monitoring, which is likely to result in more efficient and comprehensive healthcare research. Nevertheless, the existing regulatory framework in India continues to be fragmented and predominantly practitioner-oriented and does not include legislation and formalized guidelines specific to AI in order to adjust to the challenges posed by AI tools in clinical studies. Through general literature review and discussion on the existing measures and regulations, this paper endorsed key regulatory loopholes, including algorithmic participation of interested parties. The research paper also examines the role of the regulatory agencies such as CDSCO (Central Drugs Standard Control Organization) and ICMR (Indian Council of Medical Research), the largely agency that is associated with medical research in comparing the India reach with international systems to elicit areas where changes and amendments can be made. Indicating the point at which a determined, risk-based method to regulation, the study endorses a potent, clear and adaptable governance models that emphasize on ethical principles, inclusivity and trust. The main principles include the establishment of India-specific AI regulatory frameworks, capacity building amid regulators, encouragement of cross-disciplinary collaboration and facilitation of the data protection and validation levels. This paper is requisite to the fact that although AI has a transformative potential in the clinical trials ecosystem, the concentration on the regulatory gaps with the help of flexible, human-oriented governance is the key to the safe, inclusive, and effective results of healthcare research. This paper is an attempt to provide a comprehensive roadmap to strike a balance between innovation and safety of patient rights, as well as scientific rigour in the AI-based clinical trials in India. The contribution is especially relevant in light of India dealing with the dual issue of using the most recent technology, and the ethical aspects of research.
Keywords: Artificial intelligence, Clinical trial, ICMR, CDSCO.
LITERATURE REVIEW
Increased applications of artificial intelligence (AI) in clinical trials have drawn significant focus to both academic and policy discussion, especially due to its possible impact on resolving long-standing problems of biomedical research.[1] In the global literature, AI is often defined as a technology that can transform clinical research and can lead to improved design of a trial, faster patient recruitment, more effective data analysis, and enhanced safety monitoring consequences. Such developments are considered particularly important in jurisdictions where clinical trials were formerly slow, costly and operationally difficult.
The literature on the contributions of AI pertaining to patient recruitment is one of the most popular. Conventional ways of recruitment are usually based on the use of hand screening of patient records, which is time consuming and subject to error. Researchers remark that AI-oriented systems, combined with electronic health records and real-life health data, can quickly screen the cases of eligible participants by matching multiple and intricate inclusion and exclusion criteria to vast datasets. This has been demonstrated to cut down the delays that would have been associated with the recruitment process and enhance efficiency of enrolment. Recruitment through AI is frequently mentioned as a solution to more representative and inclusive trial cohorts in the Indian context when population diversity and ineffective healthcare delivery are also a challenge in addition to other difficulties.[2]
The use of AI in data analysis and safety surveillance is also a topic of academic writing. Clinical trials usually produce huge amounts of information, some of which cannot be comprehended using standard statistical tools alone. Machine learning algorithms can identify patterns, correlations and safety indicators that can not be easily noticed by human researchers.[3] Literature indicates that literature can support participant safety and enhance the overall trial reliability by enabling continuous, real-time monitoring with the help of AI and identifying unfavorable occurrences and inconsistencies with the anticipated results[4].
Although these advantages have been identified, the literature generally warns against the uncontrolled or unthoughtful application of AI in clinical trials. Among the most often discussed issues is to do with algorithmic prejudice. The learning process of AI systems is based on past data and in case this data mirror pre-existing social, economic or medical imbalances, then the model will replicate or even enhance such imbalances. This may cause systematic exclusion of some groups in the clinical trials including women, rural populations, or the disadvantaged in the economy. According to scholars, biased algorithms do not only compromise the ethical values of being fair, but also hamper the scientific validity and generalisability of trial outcomes.[5]
The other significant issue that is recorded in the literature is the question of transparency and explainability. Most sophisticated AI systems are used as black boxes in which they provide their results without transparent descriptions of decision-making processes. This insider trading creates problems to researchers and ethics committees who have to justify trial decisions especially when AI results have a bearing on important elements like the eligibility of the patients, safety checks or treatment reactions. As noted in the literature, also problematic in terms of regulatory oversight is the low explainability, and this fact casts serious doubts about the accountability in instances where AI-assisted decisions harm.[6]
Another theme of importance in the existing scholarship is data protection and patient privacy. The use of AI in clinical trials demands sensitive health information such as medical histories, genetic data and behavioural data. Researchers highlight the fact that ineffective data-governance systems raise the chances of unauthorised access, breach of data and misuse of personal information.[7] Such issues are especially sharp in such countries as India, where the level of digital infrastructure and cybersecurity preparedness also differ greatly between institutions. It has been noted in the literature that the lack of uniformity in informed-consent practices and data-security standards can undermine the trust of the population in clinical research when not managed. In the Indian regulatory environment, the academic literature identifies an increased role of institutional organisations like the Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organisation (CDSCO). The ICMR is usually referred to as the main ethical body in biomedical research. Its ethical code emphasizes the main principles of respecting patient autonomy, to the informed consent, justice, transparency, and the importance of human control when AI is involved in research. Responsible use of AI The significance of these principles in responsible AI use is generally recognized by scholars. Simultaneously, the literature states that these guidelines are mostly advisory and lack specific and enforceable standards of algorithms validation and continuous monitoring of performance. [8]
The role of the CDSCO is considered primarily concerning regulatory measures of safety and scientific integrity of clinical trials. Whereas the current clinical trial regulations had not been made with AI-based tools in mind, it has been noted that the CDSCO has been rather accommodating in relation to digital and AI-driven technologies. The use of AI-generated evidence is playing a growing role in the existing approval pathways through consultations, expert committees and changing regulatory practices. Nevertheless, researchers always note that there are no clear operational guidelines on the problems of auditing algorithms, accountability of automated decisions and post-deployment monitoring, leading to uneven regulatory practices across trial locations.
Some of them are comparative in nature and seek to analyse international regulatory frameworks designed by organisations like the World Health Organization, the European Medicines Agency and the United States Food and Drug Administration. They tend to be based on risk-based categorizing AI systems, the requirement of mandatory audits, the need to explain, and constant monitoring. Although it is common that such models have been discussed as the useful reference points, some scholars have warned that transplanting directly into the context of India may not be practical because of institutional capacity and availability of resources. Rather, literature implies preferential adaptation of these strategies to local realities. [9]
RESEARCH GAP
Although the literature about artificial intelligence in clinical trials grows, there are still a number of critical gaps.First, despite the fact that the ethical principles developed by such organizations as the ICMR are well-documented, the literature is rather silent on the topic of how these principles can be transformed into the enforceable regulatory principles applied to algorithm validation, transparency, auditability, and ongoing supervision of Indian clinical trials.
Second, the literature is inclined to examine functions of the ICMR and CDSCO individually, paying less attention to how coordinated regulation activity and mutual responsibility might work in the framework of one system of governance of AI-enabled research.
Third, although the international regulatory models are often talked about, little is done to investigate how the risk-based AI governance systems could suit the Indian unique institutional environment, such as uneven infrastructure, unstable regulatory capacity, and unequal distribution of research centers.
Last but not least, current research fails to answer the questions of accountability, especially in terms of responsibility in cases where AI-aided decisions cause harm to the trial participants and how this responsibility ought to be organized in the context of the Indian regulatory system.
In this study, the researcher aims to fill these gaps by studying the intersection of ethical guidance, regulatory practice and institutional capacity and also proposes a context-specific governance framework capable of balancing between innovation and patient safety, accountability and scientific integrity in AI-assisted clinical trials in India.
INTRODUCTION
Artificial intelligence (AI) has started playing a major role in many areas of healthcare, and one of the spheres where its effects have become more pronounced is clinical trials. During the process of developing new medicines, vaccines, or medical interventions, clinical trials are very important. However, in India, clinical research has always been a sluggish and resource-heavy procedure. The process of introducing new treatments to the population is often slowed down by the necessity to handle large amounts of data, recruit a sample of various populations, and adhere to complicated protocols of the trials. These issues have been long-standing problems on the efficiency, cost, and general effectiveness of clinical research in the country.[10]
This situation has begun to change with the introduction of AI technologies. The predictive algorithms, machine learning models, and automated data monitoring systems, which are the AI tools, are slowly transforming the clinical trial landscape. Researchers are using these technologies to help them design more effective trials, find the right patients faster, analyse complicated datasets and monitor patient safety on a continuous basis. AI has the capability to identify patterns or trends that data might contain that are challenging or time-intensive to discover by humans. This has resulted in faster clinical trial testing, enhanced precision and less operational load. [11]This is a silent yet a promising change on how healthcare research can be better fruitful and thorough.[12]
Although these benefits are in place, there are also various problems that arise as a result of using AI in clinical trials. Although AI can enhance clinical research, it presents significant issues regarding the quality of data, its transparency, accountability, and privacy of a patient. An example is that partial or biased data will cause inaccurate data, and a lack of transparency in the process of deciding by an algorithm will cause one to struggle to comprehend how a conclusion is formed. Moreover, sensitive health information can be used, and this will expose privacy invasion, thereby diminishing confidence in the clinical research. These problems have a direct impact on the reliability, safety and ethical acceptability of trial outcomes.[13]
The healthcare system in India has other complications in this regard. It encompasses research institutions of high technical potential and resource constrained centres that do not have sufficient digital infrastructure.[14] Disproportionate access to technology, the lack of trained staff, and ignorance of how AI tools ought to be utilized in a responsible manner continues to be a problem in many hospitals and research teams. Such an unequal ability complicates the adoption of AI in a meaningful and fair way to take place throughout the country. The advantages of AI can only be enjoyed in a handful of institutions equipped with the necessary resources to do that without adequate guidance and support, further expanding the disparities in healthcare research.
Aware of such trends, the Indian government and regulators are starting to act in order to address the increasing application of AI to medical research. Major organisations like the Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organisation (CDSCO) have recommended ethical codes and advisory reports and policy statements to encourage the safe and responsible use of AI. Such attempts are indications of readiness to be changed by technology and accept the necessity of governmental regulation. Nevertheless, these steps are still in their nascent phase, and they do not have the more AI-specific frameworks that can be used to tackle the emergent risks in a uniform and enforceable way.
It is against this backdrop that this research paper considers the two-sidedness of AI in Indian clinical trials. It delves into the advantages of AI technologies and the threats that they bring along with regulatory steps that have been taken. The study will not concentrate mainly on the legal provisions, but it will be interested in the practical implications of AI on the clinical research ecosystem. The paper aims at establishing the priorities that should be considered in ethical, safe, and effective use of AI in medical researches by examining the existing literature, policy endeavors, and regulatory practices. By so doing, it reveals the necessity to have a balanced and prospective strategies that will enable India to embrace technological innovation without violating the rights of patients, research integrity, and public trust.
METHODOLOGY
The research design chosen in this study is qualitative and exploratory to investigate how India is slowly developing its regulatory framework to facilitate the introduction of artificial intelligence (AI) into clinical trials. A qualitative method was believed to suit considering the fact that AI use in clinical research is a developing phenomenon in India and regulatory activities are still in developmental stages. The study is exploratory, which makes it possible to obtain a more flexible and in-depth overview of the tendencies in the policy, the institutional reactions, and the practical issues related to the AI-facilitated clinical trials.[15]
The study lays specific focus on the functions and changing statuses of the two key regulatory bodies of clinical research regulation in India, which include the Central Drugs Standard Control Organisation (CDSCO) and the Indian Council of Medical Research (ICMR). These organizations are key to the regulation, control, and direction of clinical trials in India and thus are important in the context of the current state of AI addressed in the regulatory sector. India has not yet enacted extensive, AI-specific laws to regulate biomedical research, and therefore the research is predominantly based on the secondary sources assessing current trends and the opinions of experts.[16]
The study data were gathered with the help of systematic search of the scholarly articles, policy papers and ethical guidelines, regulatory notifications, and official reports provided by national and international organisations. Ethical guidelines, advisories, discussion papers, and consultation drafts that were published by the CDSCO and ICMR were given special attention. These papers were evaluated to grasp the regulatory purpose, ethical interests, and viable anticipations on researchers who apply AI in clinical trials. Also, clinician, ethicist, research and industry stakeholder commentaries and position papers were reviewed to obtain on-the-ground views and implementation issues.[17] To have a greater point of reference, the works of international regulatory organizations like the World Health Organization (WHO), the European Medicines Agency (EMA), and the United States Food and Drug Administration (FDA) were examined. These sources were utilized solely in the form of a comparative points of reference to put light on the differences and similarities in the approaches of regulations, but the main analytical focus was also strongly on the national context of India.[18]
The review was done in a thematic way. All the considered sources were grouped into three broad themes (i) the potential use of AI in clinical trials and its limitations, (ii) ethical, technical, and governance risks of advanced AI systems, (iii) current and proposed regulatory actions of Indian authorities. All the themes were critically assessed in a bid to determine recurring trends, strengths of current practices, areas of weaknesses in terms of regulatory gaps as well as where guidance is limited or rather vague. The analysis did not consider AI adoption solely as a technological change process, as it purposefully included more extensive aspects, including the ethics of research, data regulation, institutional ability, transparency of algorithms, and equal access. Lacking a specific statutory framework of AI in the clinical trials, the study is carried out in the style of a descriptive and interpretive rather than a legalistic analysis. Such an approach will also allow a fair evaluation of both the regulatory advancement and the existing weaknesses, which will offer a solid perspective of how India is ready to regulate AI-assisted clinical research.[19]
FINDINGS
The results of this research paper suggest that artificial intelligence deployment in clinical trials in India is producing considerable operational value, as well as, uncovering critical regulatory, ethical, and infrastructural issues. Regulatory authorities like the ICMR or the CDSCO have made the first steps in regards to the problem of AI, which may be interpreted as indicating the increasing realization of the necessity of regulation. Nevertheless, such answers are still highly informative and piecemeal, indicating the infantile nature of the regulation in this field.[20]
The benefits of AI in Clinical Trials
The acceleration of the patient recruitment is one of the most remarkable advantages of AI in clinical trials. Using AI-based applications can help identify patients who fit complex eligibility criteria through electronic health records and hospital databases and real-world health data quickly and at scale. This saves a lot of time and effort that was normally needed in the manual screening process and the trials are able to achieve enrolment targets sooner and conserve delays that have historically plagued clinical research in India.[21]
The accuracy of data analysis and interpretation is also increased with AI. Machine learning algorithms can be especially useful when extensive data sets are involved, along with complex data sets that are not readily recognizable by a human researcher. This makes the outcomes of trials more accurate and consistent particularly in safety monitoring, biomarker analysis and evaluation of response to the treatment. AI helps increase the accuracy and consistency of scientific results by minimizing the role of human error and interpretation.
Other key benefits include cost efficiency. Repetitive tasks like data entry, data cleaning, data query resolution and preliminary statistical analysis are automated, hence lessening reliance on manual labour. These efficiencies contribute to the reduction of the cost of operations, and increasing the speed of the trial process, so that clinical research is more economical to sponsors and institutions.[22]
Safety monitoring is also enhanced by AI-driven systems because it is continuously and in real-time monitored. Through a stream of patient data, AI can efficiently identify adverse events or when the safety trend is not going as anticipated once it is being generated. The timely correction of a research action can be achieved by early detection and thereby enhances the protection and safety of the participants during the trial.
Lastly, AI will promote demographic inclusiveness in clinical trials. Responsibly designed AI tools may target eligible participants representing under-represented groups by analysing a variety of geographic, socioeconomic, and demographic data. This will assist in generating study cohorts which is more representative of the heterogeneous population in India and enhances the generalisability and equity of clinical research findings.[24]
Problems / drawbacks of AI in Clinical Trials
Although it has a high potential to enhance efficiency and accuracy, the application of artificial intelligence (AI) in clinical trials has a number of challenges which should be taken into consideration. Unless these issues are addressed in the right way, they might compromise the scientific integrity of trials, jeopardize the safety of participants, and undermine the public confidence in AI-assisted medical research.[25]
Algorithms bias is one of the gravest issues. AI systems are trained on historical data, and when these data are incomplete, unrepresentative, or a result of the current social and medical inequalities, the systems can be trained to replicate or even enhance these biases. When applied to clinical trials, it may result in the systematic exclusion of some groups of people, including women, rural groups, or socioeconomically disadvantaged groups. The use of biased algorithms could also lead to an inaccurate risk-benefit evaluation, including the decision regarding patient eligibility or treatment distribution. The consequences of this research are dangerous to both ethical standards of fairness and scientific validity of research results.[26]
The other significant difficulty is the possibility of inaccurate inference. Poor-quality data can be used to train AI models that can provide inaccurate forecasts on the efficacy of treatment, adverse events, or patient suitability. The excessive use of algorithmic result without adequate review by humans can lead to a breach of trial integrity. In worst-case scenarios, inaccurate AI-based suggestions can put the participants at risk of which they are not or deprive them of possible effective treatments. This is why there should be strict standards of validation and constant human supervision.[27]
The issue of data privacy and data security is also a major challenge. Clinical trials based on AI are dependent on massive amounts of sensitive health data, as medical records, genetic, and behavioural data. It is necessary to make sure that the storage, access, and transmission of data are safe. Nonetheless, in India, the presence of unequal cybersecurity readiness rates and inconsistency in informed-consent functioning in different institutions raises the possibility of data breach and unauthorised disclosures. This may have detrimental effects on participants and undermine people’s trust in clinical studies.[28]
The unaccountability, commonly known as the black-box problem, also makes the adoption of AI a further issue. Several advanced models of AI fail to specify how such models arrive at a certain conclusion or recommendation.[29] This obscurity complicates the verification of algorithmic decisions by researchers, ethics committees and regulators, and the challenge of such decisions. In cases where AI outputs affect vital trial decisions, low explainability generates accountability issues alongside undermining regulatory controls.[30]
In the case of regulatory and institutional initiatives
The swift penetration of artificial intelligence (AI) into clinical trials has forced the Indian regulatory bodies to emphasize more on the creation of governance frameworks that will guarantee ethical, safe, and responsible application of AI.[31] Although AI has a lot of positive aspects like better efficiency, data analysis, and uninterrupted safety, it also presents complicated issues. These are associated with the risks of algorithm bias, transparency deficit in algorithmic decision-making, and more vulnerable sensitive patient information. These issues can kill scientific credibility and jeopardize the rights and safety of study subjects, should they be uncontrollable. Regulatory and institutional oversight in this sense have taken center stage in the process of influencing adoption of AI in the Indian clinical research ecosystem.
The two important institutions in India that are tasked with the responsibility of supervising clinical trials are the Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organisation (CDSCO).[32] Even though neither of the bodies has taken a wholesome regulatory framework directly focused on AI in clinical research, the two have made significant early steps that are indicative of increased awareness regarding the implications of AI. Combined, these initiatives constitute a base of a new regulatory framework that aims at striking a balance between innovation and ethical accountability.
It is the ICMR that has been on the forefront in dealing with the ethical aspects of AI implementation in healthcare research. In its ethical principles and guidance documents, the ICMR has stressed on such essential principles as respect of patient autonomy, informed consent, data privacy, and fairness. These principles make researchers make sure that there is transparency in the application of AI systems, and that they are accountable to decisions made under the influence of algorithmic tools. The ICMR has also emphasized the role of human oversight and thus it is evident that AI should be used to aid and not to substitute human judgment in clinical research. Although these are mostly principle-based and not binding, they offer a significant ethical framework of which AI-enabled research will likely be functioning.[33]
As the national drug regulatory authority of India, the CDSCO has been paying attention to the scientific and procedural integrity of clinical trials. Its current regulations were not tailored to the AI, but the CDSCO has started to become involved with digital health innovations by conducting consultations, expert committees, and changing guidelines on the conduct of clinical trials and data management. Its regulatory capabilities are also important in the framework of maintaining safety, quality and efficacy standards of AI-enabled trials. Nonetheless, the fact that there is no specific operational standard of AI constrains the uniformity with which such supervision can be conducted.[34]
The combined effort of the ICMR and the CDSCO can be seen as an adaptive and incremental methodology of regulation. Instead of using strict measures in the early years, the Indian authorities seem to be keeping a stalk on the changes in technology and preparing ethical and institutional ground. However, this discontinuous and mostly advisory strategy also brings about regulatory gaps especially on areas where verification of the algorithms, accountability of automated decisions are not well set and enforcement mechanisms. Due to the ongoing development of AI and its increasing integration into the clinical research, there becomes a clear necessity to implement more and more technology-specific regulations that expand on those early attempts. Enhancing the capacity of the institutions, the inter-agency coordination, and the translation of the ethical principles into enforceable standards will be crucial to making sure that AI will contribute to the improvement of the clinical trial ecosystem in India.
These policymaking and policy implementation activities are manifested in a number of inter-related activities that constitute the basis of a developing governance framework of artificial intelligence (AI) in clinical trials in India. Although these measures are premature, and have not been so far incorporated into one binding regulatory code, they reflect an effort by Indian authorities and research facilities to react in a systematic way to the opportunities and threats posed by AI-enabled clinical research.
One of the key pillars of this changing structure is the ethical code as published by Indian Council of Medical Research (ICMR).[35] ICMR developed a series of general ethical principles that govern the application of AI and machine-learning systems to health research. Such principles highlight the need to keep the operations of AI systems transparent, deliver justice, hold decision makers accountable through algorithms, and the need to have human involvement in AI operations. The ICMR emphasizes the role of researcher responsibility and ethical judgment by placing it in a clear position on the fact that AI needs to support human judgment and not to substitute it. Such requirements offer the investigators and ethics committees a moral and functional reference point so that they can ultimately find out the possible risks and how the aptness of AI tools as well as safeguard the research participants better in AI-aided clinical trials.
The Central Drugs Standard Control Organisation (CDSCO) has taken a pragmatic and accommodative position on emerging technologies in addition to the ethical leadership of the ICMR. In spite of the fact that the current clinical trial regulations were not initially created to deal with AI, the CDSCO has demonstrated willingness to work with AI-enabled processes, especially in the fields of pharmacovigilance, safety reporting, and real-time data integrity monitoring.[36] The CDSCO has indicated that AI-based evidence and tools can be addressed in the current regulatory channels, however, sufficient validation, documentation, and risk reduction measures must be provided. Such a flexible attitude can be traced to a changing regulatory philosophy which acknowledges the necessity of changing oversight mechanisms in reaction to the rapid change of technology and which upholds the standards of safety and scientific rigour.
The other important development has been the introduction of special institutional review mechanisms in major research organisations and academic institutions. In reaction to national recommendations and code of conducts, various institutions have established specific committees or sub-groups tasked with the role of screening the application of AI in clinical research. Those bodies evaluate the quality and representativeness of the training data and test the measures of model performance, and adherence to ethical principles and data-protection. These mechanisms can increase the internal accountability and decrease the probability of blindly or indiscriminately using AI tools in clinical trials by the institutional review processes introducing AI-specific scrutiny.
Both the ICMR and CDSCO have also endorsed a risk-stratified approach to regulatory oversight.[37] This approach recognises that not all AI applications carry the same level of risk. Low-impact tools used for administrative automation or data organisation may warrant lighter oversight, while high-stakes AI systems that influence patient selection, treatment decisions, or safety assessments require more rigorous review. By tailoring regulatory intensity to the level of risk posed by each application, this proportionate model offers the flexibility needed to keep regulation relevant in a fast-evolving technological environment.
Finally, there is a growing and deliberate emphasis on human capacity development. Policymakers and regulators increasingly recognise that ethical guidelines and regulatory frameworks alone are insufficient without skilled personnel to implement them effectively. [38]As a result, efforts are being made to improve AI literacy among regulators, ethics committee members, and clinical investigators through training programmes, workshops, and interdisciplinary collaboration. These initiatives aim to equip stakeholders with the knowledge needed to assess algorithmic reliability, understand validation studies, and exercise informed oversight.
Taken together, these measures spanning ethical guidance, regulatory openness, institutional innovation, risk-based supervision, and capacity building indicate that India is steadily constructing a multi-layered governance ecosystem for AI in clinical trials. Although significant gaps remain, particularly the absence of enforceable technical standards and uniform validation protocols, the direction of progress is clear. India is moving from an ad hoc and reactive approach toward a more structured, forward-looking regulatory framework that seeks to harness AI’s transformative potential while upholding the core principles of ethical research and participant protection.
The potential and governance bridge: AI in the clinical trial ecosystem of India
The application of artificial intelligence (AI) in the clinical trial ecosystem of India is a clear picture of potential advantages and severe governance issues. On the one hand, AI proved to enhance clinical trials, as it allows recruiting patients quicker, conducting data analysis more profoundly, and monitoring safety in the long run. These are the benefits which can sometimes be beyond the reach of the normal research methods. These advantages, on the contrary, do not come on their own. The key factor to their success is the capacity of institutions in dealing with risks, to facilitate ethical use as well as to offer proper supervision. In absence of appropriate governing, AI tools might end up making new issues rather than addressing the old ones.[39]
The AI has obviously enhanced the efficiency and quality of trials in research centres which are well furnished with stable digital infrastructure and well trained personnel. Artificial intelligence may help such centres manage complicated data sets, address safety issues beforehand, and simplify trials processes. But, in less-resourced environments, as are found in most of India, things are far otherwise. The inadequate infrastructure, bad quality of data, and untrained personnel may result in AI systems giving incorrect results, supporting the existing biases, or making sensitive patient information vulnerable to security threats. Rather than making the world less unequal, AI can thus increase the disparity between big research institutions and poorly-resourced trial sites.[40]
A well-developed and sophisticated regulatory framework is one of the primary causes of such risks. Currently, there are no specific and explicit rules that can be enforced by the Indian policies with regard to the validation, transparency and accountability of AI systems involved in clinical trials. No standardised rules exist that make researchers describe how algorithms come to a decision, demonstrate that models are not biased or create accountability when AI-advantaged decisions lead to harm. Subsequently, there are diverse practices in the institutions. The AI implementation is frequently determined by all-local considerations and available resources instead of national standards. This ambiguity is a severe gap in governance in a professional area where errors may have a direct impact on patient safety and scientific integrity.
The measures of regulatory agencies; Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organisation (CDSCO) are pivotal yet minimal. The ethical principles of the ICMR are justifiably concerned with impartiality, openness, responsibility, and human involvement. On the same note, the CDSCO is open to submissions which are technology-driven implying it is willing to embrace innovation. The latter are, however, largely advisory measures. They do not include binding technical specifications on testing of algorithms, audit and continuous performance monitoring mechanisms. This limits their capacity to have uniform and quality AI application processes within the country.[41]
An international experience can offer some valuable lessons in this aspect. In more advanced AI government frameworks, it is common to have independent auditing prior to the implementation of AI tools, marked line-item accountability of the algorithmic decision-making, and active post-implementation supervision. Such systems also spend a lot of money in training regulators and researchers who are supposed to be familiar with AI technologies. Although India cannot afford to imitate these models because of the variation in resources and infrastructure, selective implementation of such standards will go a long way in enhancing domestic control without burdening the regulatory system.
Finally, this discussion shows that there is a necessity of human-centred approach to regulation. Although AI can improve the speed and analytical capabilities, clinical judgment, ethical or contextual reasoning cannot be substituted. Clinical trials with AI should also be used sustainably, and to achieve this, governance systems capable of strengthening human oversight and not undermining it are needed. This involves standards that are enforceable, training of professionals in professional training that is on continuous basis and the institutional structures that help in the continuous review and accountability.[42] Such an even-handed approach is the only way in which India will be able to make AI genuinely support the clinical research – promote innovation and better patient outcomes without touching the ethical integrity and scientific rigour.[43]
CONCLUSION
One of the most fundamental changes to modern Indian biomedical research is the implementation of artificial intelligence into the clinical trials. The facts provided in this paper indicate clearly that AI tools have the potential to fundamentally transform the behaviour of clinical research: by drastically shortening the registration timeframes, increasing data interpretation accuracy, decreasing the total expenditure, and providing real-time information that has a significant impact on the safety of participants. The capabilities provide a rare chance to a country with a long history of structural limitations, a booming pharmaceutical industry, and rapidly growing digital-health infrastructure to transform the Indian clinical researcher to the utmost standards of efficiency, inclusiveness, and scientific rigour.
But this transformative possibility can never exist independently of at least equally high threats. Algorithms bias, inability to be interpreted, violations of patient privacy, structural inequalities that cannot be fixed, and insufficient AI literacy of most researchers and ethics review boards are the obstacles that go well beyond technical failure. They hit at the core of research integrity and welfare of the participant. Without stringent validation and the continuous monitoring, AI systems may negatively affect the clinical decision-making process, yield false evidence, or put vulnerable members at a risk of harm previously unknown that is magnified in the environment where digital maturity and specialised expertise is not equally distributed. The current level of technological and regulatory advancement in India makes such issues especially sharp and calls on a deliberate, cautious, and ruthless approach to integration.
It is promising, thus, that some of the key oversight institutions in the country the Indian Council of Medical Research and the Central Drugs Standard Control Organisation have started to take action. The ethics code of the ICMR has set out an articulate set of ethics, in terms of fairness, transparency, accountability and the primacy of human well-being, and has given investigators and ethics committees an indispensable moral compass. Parallel to this, the CDSCO has indicated an increased willingness to embrace AI in the current and future regulatory procedures. These measures are expected to become a significant change in the institutional thinking and are a fundamental basis of stronger governance.
[1] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021).
[2] Indian Council of Medical Research, Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare (2023) (India).
[3] Suchi Saria et al., Artificial Intelligence in Clinical Trials, 11 CLINICAL PHARMACOLOGY & THERAPEUTICS 1, 4–6 (2022).
[4] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021),
[5] Indian Council of Medical Research, Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare (2023) (India).
[6] European Commission, Proposal for a Regulation Laying Down Harmonised Rules on Artificial Intelligence (Artificial Intelligence Act), COM (2021) 206 final.
[7] Indian Council of Medical Research, National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017, updated 2023) (India).
[8] Indian Council of Medical Research, Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017, updated 2023) (India).
[9] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021),
[10] World Health Organization, Guidance on Artificial Intelligence in Clinical Research (2022).
[11] Suchi Saria et al., Artificial Intelligence in Clinical Trials, 11 CLINICAL PHARMACOLOGY & THERAPEUTICS 1, 4–6 (2022).
[12] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021),
[13] European Commission, Proposal for a Regulation Laying Down Harmonised Rules on Artificial Intelligence (Artificial Intelligence Act), COM (2021) 206 final.
[14] NITI Aayog, National Strategy for Artificial Intelligence: #AIforAll (2018).
[15] H.W. Perry, Deciding to Decide: Agenda Setting in the United States Supreme Court 12–14 (1991).
[16] Central Drugs Standard Control Organisation, New Drugs and Clinical Trials Rules, 2019 (India); Indian Council of Medical Research, Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare (2023) (India).
[17] World Health Organization, Guidance on Artificial Intelligence in Clinical Research (2022).
[18] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021); European Medicines Agency, Regulatory Science to 2025 (2020); U.S. Food & Drug Administration, Artificial Intelligence and Machine Learning in Drug Development (2023).
[19] NITI Aayog, National Strategy for Artificial Intelligence: #AIforAll (2018).
[20] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021),
[21] World Health Organization, Guidance on Artificial Intelligence in Clinical Research (2022).
[22] European Commission, Proposal for a Regulation Laying Down Harmonised Rules on Artificial Intelligence (Artificial Intelligence Act), COM (2021) 206 final.
[23] World Health Organization, Guidance on Artificial Intelligence in Clinical Research (2022).
[24] Indian Council of Medical Research, Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare (2023) (India).
[25] NITI Aayog, Responsible AI for All (2021),
[26] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021),
[27] Indian Council of Medical Research, Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare (2023) (India).
[28] NITI Aayog, Responsible AI for All (2021),
[29] European Commission, Artificial Intelligence Act, COM (2021) 206 final.
[30] ¹² Indian Council of Medical Research, Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare (2023) (India).
[31] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021).
[32] Central Drugs Standard Control Organisation, New Drugs and Clinical Trials Rules, 2019 (India); Indian Council of Medical Research, Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare (2023) (India).
[33] Indian Council of Medical Research, Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare (2023) (India).
[34] Central Drugs Standard Control Organisation, New Drugs and Clinical Trials Rules, 2019 (India).
[35] Indian Council of Medical Research, National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017, updated 2023) (India).
[36] World Health Organization, Guidance on Artificial Intelligence in Clinical Research (2022).
[37] European Commission, Proposal for a Regulation Laying Down Harmonised Rules on Artificial Intelligence (Artificial Intelligence Act), COM (2021) 206 final.
[38] NITI Aayog, Responsible AI for All (2021).
[39] U.S. Food & Drug Administration, Artificial Intelligence and Machine Learning in Drug Development (2023).
[40] Suchi Saria et al., Artificial Intelligence in Clinical Trials, 11 CLINICAL
[41] Central Drugs Standard Control Organisation, New Drugs and Clinical Trials Rules, 2019 (India).
[42] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021).
[43] World Health Organization, Ethics and Governance of Artificial Intelligence for Health (June 28, 2021).
